Small molecule Bruton's tyrosine kinase (BTK) inhibitors have been developed for the treatment of various haemato-oncological diseases, and ibrutinib was approved as the first BTK inhibitor for anticancer therapy in 2013. Previous reports proved the receptor kinase human epidermal growth factor receptor 2 (HER2) to be a valid off-target kinase of ibrutinib and potentially other irreversible BTK inhibitors, as it possesses a druggable cysteine residue in the active site of the enzyme. These findings suggest ibrutinib as a candidate drug for repositioning in HER2-positive breast cancer (BCa). This subtype of breast cancer belongs to one of the most common classes of breast tumours, and its prognosis is characterized by a high rate of recurrence and tumour invasiveness. Based on their similar kinase selectivity profiles, we investigated the anticancer effect of zanubrutinib, evobrutinib, tirabrutinib and acalabrutinib in different BCa cell lines and sought to determine whether it is linked with targeting the epidermal growth factor receptor family (ERBB) pathway. We found that zanubrutinib is a potential inhibitor of the HER2 signalling pathway, displaying an antiproliferative effect in HER2-positive BCa cell lines. Zanubrutinib effectively inhibits the phosphorylation of proteins in the ERBB signalling cascade, including the downstream kinases Akt and ERK, which mediate key signals ensuring the survival and proliferation of cancer cells. We thus propose zanubrutinib as another suitable candidate for repurposing in HER2-amplified solid tumours.

Department of Experimental Biology Faculty of Science Palacký University Olomouc Šlechtitelů 27 78371 Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University Olomouc Hněvotínská 5 77900 Olomouc Czech Republic

See more in PubMed

Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006;439:168–174. doi: 10.1038/nature04177. PubMed DOI

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553–563. doi: 10.1038/nrc3309. PubMed DOI

Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer. 2021;7:56. doi: 10.1038/s41523-021-00265-1. PubMed DOI PMC

Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast Cancer. Front Oncol. 2012;2:62. doi: 10.3389/fonc.2012.00062. PubMed DOI PMC

Kreutzfeldt J, Rozeboom B, Dey N, De P. The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am J Cancer Res. 2020;10:1045–1067. PubMed PMC

Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive human xenograft Tumor Models. Cancer Res. 2009;69:9330–9336. doi: 10.1158/0008-5472.CAN-08-4597. PubMed DOI

Hicks M, Macrae ER, Abdel-Rasoul M, et al. Neoadjuvant Dual HER2-Targeted Therapy with Lapatinib and Trastuzumab improves pathologic complete response in patients with early stage HER2-Positive breast Cancer: a Meta-analysis of randomized prospective clinical trials. Oncologist. 2015;20:337–343. doi: 10.1634/theoncologist.2014-0334. PubMed DOI PMC

Wahdan-Alaswad R, Liu B, Thor AD. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resist. 2020;3:179–198. doi: 10.20517/cdr.2019.92. PubMed DOI PMC

Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in Clinical Development for B-Cell Malignancies. Blood. 2018;132:1871–1871. doi: 10.1182/blood-2018-99-109973. PubMed DOI

Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse Effects. Front Cell Dev Biol. 2021;9:630942. doi: 10.3389/fcell.2021.630942. PubMed DOI PMC

Shi Y, Guryanova OA, Zhou W, et al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci Transl Med. 2018;10:eaah6816. doi: 10.1126/scitranslmed.aah6816. PubMed DOI PMC

Zhu S, Gokhale S, Jung J, et al. Multifaceted Immunomodulatory Effects of the BTK inhibitors Ibrutinib and Acalabrutinib on different Immune Cell Subsets – Beyond B Lymphocytes. Front Cell Dev Biol. 2021;9:727531. doi: 10.3389/fcell.2021.727531. PubMed DOI PMC

Gao W, Wang M, Wang L, et al. Selective Antitumor activity of Ibrutinib in EGFR-Mutant non–small cell Lung Cancer cells. JNCI J Natl Cancer Inst. 2014;106:dju204. doi: 10.1093/jnci/dju204. PubMed DOI PMC

Cortes JE, Jonas BA, Graef T, et al. Clinical experience with Ibrutinib alone or in combination with either cytarabine or azacitidine in patients with Acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019;19:509–515e1. doi: 10.1016/j.clml.2019.05.008. PubMed DOI

Kim DW, Tan E, Zhou J-M, et al. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Br J Cancer. 2021;124:1803–1808. doi: 10.1038/s41416-021-01368-z. PubMed DOI PMC

Pachynski R, Reimers M, Weimholt C, et al. 423 a phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer. J Immunother Cancer. 2021;9:A453–A453. doi: 10.1136/jitc-2021-SITC2021.423. DOI

Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol. 2010;14:475–480. doi: 10.1016/j.cbpa.2010.06.168. PubMed DOI

Rauf F, Festa F, Park JG, et al. Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene. 2018;37:2237–2250. doi: 10.1038/s41388-017-0079-x. PubMed DOI PMC

Chen J, Kinoshita T, Sukbuntherng J, et al. Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther. 2016;15:2835–2844. doi: 10.1158/1535-7163.MCT-15-0923. PubMed DOI

Wang A, Yan X-E, Wu H, et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget. 2016;7:69760–69769. doi: 10.18632/oncotarget.11951. PubMed DOI PMC

Muñoz J, Paludo J, Sarosiek S, Castillo JJ. Coming of age for BTK inhibitor therapy: a review of Zanubrutinib in Waldenström Macroglobulinemia. Cells. 2022;11:3287. doi: 10.3390/cells11203287. PubMed DOI PMC

Guo Y, Liu Y, Hu N, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62:7923–7940. doi: 10.1021/acs.jmedchem.9b00687. PubMed DOI

Crawford JJ, Johnson AR, Misner DL, et al. Discovery of GDC-0853: a potent, selective, and Noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J Med Chem. 2018;61:2227–2245. doi: 10.1021/acs.jmedchem.7b01712. PubMed DOI

Dai X, Cheng H, Bai Z, Li J. Breast Cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8:3131–3141. doi: 10.7150/jca.18457. PubMed DOI PMC

Tanner M, Kapanen AI, Junttila T, et al. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Mol Cancer Ther. 2004;3:1585–1592. doi: 10.1158/1535-7163.1585.3.12. PubMed DOI

Grant S, Qiao L, Dent P. Roles of Erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 2002;7:d376–d389. doi: 10.2741/grant. PubMed DOI

Lim S-J, Lopez-Berestein G, Hung M-C, et al. Grb2 downregulation leads to akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 2000;19:6271–6276. doi: 10.1038/sj.onc.1204014. PubMed DOI

Falls D. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14–30. doi: 10.1016/S0014-4827(02)00102-7. PubMed DOI

Wang X, Wong J, Sevinsky CJ, et al. Bruton’s tyrosine kinase inhibitors prevent therapeutic escape in breast cancer cells. Mol Cancer Ther. 2016;15:2198–2208. doi: 10.1158/1535-7163.MCT-15-0813. PubMed DOI PMC

Grabinski N, Ewald F. Ibrutinib (Imbruvica™) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 2014;32:1096–1104. doi: 10.1007/s10637-014-0141-2. PubMed DOI

Caldwell RD, Qiu H, Askew BC, et al. Discovery of Evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of Immunological Diseases. J Med Chem. 2019;62:7643–7655. doi: 10.1021/acs.jmedchem.9b00794. PubMed DOI

Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–859. doi: 10.1182/blood.2019001160. PubMed DOI PMC

Liston DR, Davis M. Clinically relevant concentrations of Anticancer Drugs: a Guide for Nonclinical Studies. Clin Cancer Res. 2017;23:3489–3498. doi: 10.1158/1078-0432.CCR-16-3083. PubMed DOI PMC

Patel VK, Lamothe B, Ayres ML, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32:920–930. doi: 10.1038/leu.2017.321. PubMed DOI PMC

Eifert C, Wang X, Kokabee L, et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosom Cancer. 2013;52:961–975. doi: 10.1002/gcc.22091. PubMed DOI PMC

Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H. Synergistic effects of various her inhibitors in combination with IGF-1R, C-MET and src targeting agents in breast cancer cell lines. Sci Rep. 2017;7:3964. doi: 10.1038/s41598-017-04301-8. PubMed DOI PMC